A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

NCT03082209 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Cancer
Hematologic Malignancies

Interventions

DRUG: ABBV-621
DRUG: Venetoclax
DRUG: Bevacizumab
DRUG: FOLFIRI

Sponsor

AbbVie